Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 150 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Stéphane G.

France

USD 150 /hr

PhD scientist with a consistent track record in drug development / Entrepreneur

Profile Summary

PhD scientist in molecular and cellular biology with a consistent track record in discovery and drug development in neurology associated with two decades of experience in diagnostic and biopharma industry. 20+ years in drug screening, target identification, assay development in pharmacogenomic, personalized medicine and neuroredenerative disorders

Subject Matter Expertise

• ★ Drug Development
• ★ Preclinical Research
• ★ Project Management
• ☆ Apoptosis
• ☆ Oxidative Stress & Mitochondrial Function
• ☆ Neuropharmacology
• ☆ Protein/Enzyme Engineering
• ☆ Clinical Trials
• ☆ Neurology
• ☆ Neuropathology
• ☆ Spinal Cord Injury
• ☆ Technical & Scientific Writing
• ☆ Grant Writing
• ☆ Fundraising
• ☆ Corporate Governance

Services

• Writing
• Research

Writing Clinical Trial Documentation, Technical Writing

Research Fact Checking, Systematic Literature Review, Secondary Data Collection

Work Experience

Freelance Consultant

AlyZ Biosciences

July 2018 - Present

Executive & Chief Scientific Officer, Founder

Neuronax

April 2016 - July 2018

Chief Executive Officer & Chief Scientifc Officer, Founder

Neuronax

March 2003 - April 2016

Executive Manager & Chief Scientific Officer, Co-Founder

Nucleica

March 1999 - June 2002

Post-Doc

Institut Pasteur

October 1998 - March 1999

Education

PhD Cellular and Molecular Biology

Université d'Auvergne

September 1992 - July 1997

Master - Genetic

Université Blaise Pascal

September 1991 - June 1992

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

(2019). SCO-Spondin Defects and Neuroinflammation Identified as Conserved Mechanisms Driving Severe Spine Deformity Across Genetic Models of Idiopathic Scoliosis . Current Biology.

(2017). SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma . Oncotarget.

(2017). Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation . Oncotarget.

(2014). SCO-spondin derived peptide NX210 induces neuroprotection in vitro and promotes fiber regrowth and functional recovery after spinal cord injury . PloS one.

(2013). Kinetics of chemically mediated neurodegeneration/neuroregeneration of mouse olfactory epithelium: monitoring by hyperlayer sedimentation field flow fractionation . Analytical and bioanalytical chemistry.

(2013). Design and validation of a colorimetric test for the genetic diagnosis of hemochromatosis using α-phosphorothioate nucleotides . Biochemical genetics.

(2008). Single-tube genotyping using a solid-phase method that combines alpha-phosphorothioate-mediated primer extension and ExoIII: proof of concept with the F508del cystic fibrosis diagnosis . Molecular and cellular probes.

(2005). Evidence for growth-promoting effects of omega n - 3 fatty acids alone and in combination with a specific vitamin and mineral complex in rat neuroblastoma cells . Nutritional neuroscience.

(2000). Subcommissural organ/Reissner's fiber complex: characterization of SCO-spondin, a glycoprotein with potent activity on neurite outgrowth . Glia.

(1999). SCO-spondin is evolutionarily conserved in the central nervous system of the chordate phylum . Neuroscience.

(1998). Complex expression pattern of the SCO-spondin gene in the bovine subcommissural organ: toward an explanation for Reissner's fiber complexity? . Brain research. Molecular brain research.

(1996). SCO-spondin: a new member of the thrombospondin family secreted by the subcommissural organ is a candidate in the modulation of neuronal aggregation. Journal of cell science.

(1996). The subcommissural organ and Reissner's fiber complex. An enigma in the central nervous system? . Progress in histochemistry and cytochemistry.